Evidence map›Paper›PMID 22315278›Full record

ReviewChest2012

Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

John W Eikelboom, Jack Hirsh, Frederick A Spencer, Trevor P Baglin, Jeffrey I Weitz

Erratum issued Registry-linked trialAbstract readComparative StudyReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chest, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02513004 (Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing "One-stop" Hybrid Coronary Revascularization), which is not on this map. Cited by 134 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 16 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02513004 phase4unknown statusnot on this mapstarted 2015, after this paper: background citation

Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing "One-stop" Hybrid Coronary Revascularization

TypeinterventionalSponsorYongjian WuRan2015 to 2017Enrolled60ConditionsCoronary DiseaseArmsTicagrelor, Clopidogrel
3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 16 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Antiplatelet agents for the treatment of adults with COVID-19.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Guideline
  15. Pooled it
  16. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.The Cochrane database of systematic reviews · 2013
    Pooled it
  17. Trial
  18. Trial
  19. Trial
  20. Trial

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

John W EikelboomDepartment of Medicine, McMaster University, Hamilton, ON, Canada; Population Health Research Institute, Hamilton, ON, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada. Electronic address: eikelbj@mcmaster.ca.
Jack HirshDepartment of Medicine, McMaster University, Hamilton, ON, Canada; Population Health Research Institute, Hamilton, ON, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada.
Frederick A SpencerDepartment of Medicine, McMaster University, Hamilton, ON, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada.
Trevor P BaglinDepartment of Haematology, Addenbrooke's NHS Trust, Cambridge, England.
Jeffrey I WeitzDepartment of Medicine, McMaster University, Hamilton, ON, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada.

Funding

Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based ClinicalR13HL104758 · NHLBI · AMERICAN COLLEGE OF CHEST PHYSICIANS · PI LEWIS, SANDRA ZELMAN · 2010 to 2010
$11k
NHLBI NIH HHS R13 HL104758
6 · The paper itself

Abstract

The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa antagonists. The relationships among dose, efficacy, and safety are discussed along with a mechanistic overview of results of randomized clinical trials. The article does not provide specific management recommendations but highlights important practical aspects of antiplatelet therapy, including optimal dosing, the variable balance between benefits and risks when antiplatelet therapies are used alone or in combination with other antiplatelet drugs in different clinical settings, and the implications of persistently high platelet reactivity despite such treatment.

Indexed as

Evidence-Based MedicinePractice Guidelines as TopicSocieties, MedicalAspirinCilostazolDipyridamoleDose-Response Relationship, DrugDrug Therapy, CombinationHumansPlatelet ActivationPlatelet AggregationPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRandomized Controlled Trials as TopicTetrazolesThienopyridinesAspirinCilostazolDipyridamolePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexTetrazolesThienopyridines

Identifiers

PMID22315278
PMCPMC3278069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.